Controls ventricular rate. ANDA 76474, held by Mylan Institutional. Esmolol Hydrochloride.
As of Nov 21, 2026, ANDA 76474 (Esmolol Hydrochloride), held by Mylan Institutional, was first approved by FDA on May 2, 2005, with 3 approved supplements and 0 published complete response letters.
1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia Esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride injection is intended for short-term use. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 2, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Esmolol Hydrochloride10MG/ML · injectable;injection | Esmolol Hydrochloride | Rx |
| Nov 7, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Nov 7, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jul 29, 2010 | Supplement 6Labeling | Approved | None posted |
| May 2, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters